Papalexandri, A.; Gavriilaki, E.; Vardi, A.; Kotsiou, N.; Demosthenous, C.; Constantinou, N.; Touloumenidou, T.; Zerva, P.; Kika, F.; Iskas, M.;
et al. Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes. Int. J. Mol. Sci. 2023, 24, 16029.
https://doi.org/10.3390/ijms242216029
AMA Style
Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N, Touloumenidou T, Zerva P, Kika F, Iskas M,
et al. Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes. International Journal of Molecular Sciences. 2023; 24(22):16029.
https://doi.org/10.3390/ijms242216029
Chicago/Turabian Style
Papalexandri, Apostolia, Eleni Gavriilaki, Anna Vardi, Nikolaos Kotsiou, Christos Demosthenous, Natassa Constantinou, Tasoula Touloumenidou, Panagiota Zerva, Fotini Kika, Michalis Iskas,
and et al. 2023. "Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes" International Journal of Molecular Sciences 24, no. 22: 16029.
https://doi.org/10.3390/ijms242216029
APA Style
Papalexandri, A., Gavriilaki, E., Vardi, A., Kotsiou, N., Demosthenous, C., Constantinou, N., Touloumenidou, T., Zerva, P., Kika, F., Iskas, M., Batsis, I., Mallouri, D., Yannaki, E., Anagnostopoulos, A., & Sakellari, I.
(2023). Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes. International Journal of Molecular Sciences, 24(22), 16029.
https://doi.org/10.3390/ijms242216029